查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1632662

鴉片類藥物使用障礙市場規模、佔有率、趨勢分析報告：按藥物、給藥途徑、分銷管道、地區、細分市場預測，2025-2030 年

Opioid Use Disorder Market Size, Share & Trends Analysis Report By Drug (Naltrexone, Buprenorphine, Methadone), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

鴉片類藥物使用障礙市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球鴉片類藥物使用障礙市場規模預計將達到102.4億美元，2025年至2030年複合年成長率為11.15%。

鴉片類藥物流行率的上升和政府應對危機的舉措不斷增加預計將推動市場成長。此外，新產品商業化的增加預計將進一步推動成長。 2018年，美國大約有290萬15歲以上的人患有這種疾病。 2016年，全國藥物使用與健康美國（NSDUH）發現，美國約有1,150萬人在上一年濫用處方鴉片類藥物，超過200萬人對處方藥上癮。

據CDC稱，每天約有130名美國死於鴉片類藥物過量攝取，美國政府已將其列為突發公共衛生事件。對於想要克服毒癮的患者來說，堅持藥物輔助治療（MAT）可以減少戒斷症狀並將死亡風險降低一半。美國FDA核准了三種 MAT 選項：Buprenornhine、美沙酮和納曲酮。每日口服Buprenornhine是標準治療方法。

近年來採取了多項措施來應對鴉片類藥物危機。例如，2016 年，CDC 發布了針對慢性疼痛處方這些藥物的臨床實踐指南，並於 2015 年採用了新的美國成癮協會實踐指南，以提高護理標準。此外，2016 年，美國FDA 宣布計劃全面改革其防止濫用的鴉片類藥物法規，加強安全標籤，並重新考慮使用的風險效益範式。

鴉片類藥物使用疾患市場報告亮點

  • Buprenornhine作為鴉片類部分致效劑的有效雙重作用而引領市場，2024年佔全球銷售額的59.58%。
  • 注射劑細分市場佔據主導地位，2024 年佔全球銷售額的 59.26%。 Vivitrol（納曲酮）和 Subrocade（Buprenornhine）等緩釋性注射劑可長時間提供穩定的藥物輸送，提高用藥依從性並降低復發風險。
  • 醫院藥局在管理複雜、嚴重病例中發揮至關重要的作用，預計到2024年，醫院藥局的市場佔有率將達到47.90%，並佔據市場主導地位。
  • 由於幾個關鍵因素，北美鴉片類藥物使用障礙市場在 2024 年佔據 68.98% 的佔有率。該地區 OUD 患病率最高，推動了對治療解決方案的巨大需求。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章鴉片類藥物使用疾患市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 鴉片類藥物使用疾患市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
  • 價格分析
  • 管道分析
  • 行為治療的質性分析

第4章鴉片類藥物使用疾患市場分析（依藥物）

  • 2024年及2030年藥品市場佔有率
  • 細分儀表板
  • 按藥物前景分類的全球鴉片類藥物使用障礙市場
  • 2018-2030年市場規模、預測及趨勢分析
    • Buprenornhine
    • 美沙酮
    • 納曲酮
    • 其他

第5章鴉片類藥物使用疾患市場分析（依給藥途徑）

  • 鴉片類藥物使用障礙：給藥途徑變化分析
  • 鴉片類藥物使用障礙市場分析，依給藥途徑分類的市場
    • 口服給藥
    • 注射給藥
    • 其他

第6章鴉片類藥物使用疾患市場分析（依通路）

  • 鴉片類藥物使用疾患：通路變化分析
  • 鴉片類藥物使用障礙市場分析（依分銷通路市場）
    • 醫院藥房
    • 零售藥房
    • 其他

第7章鴉片類藥物使用障礙市場：按藥物、給藥途徑和分銷管道分類的區域估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場簡介
  • 2018-2030年市場規模及預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • Key customers
    • Key company market share analysis, 2024
    • Indivior PLC
    • Teva Pharmaceutical Industries, Ltd.
    • Pfizer, Inc.
    • BioDelivery Sciences International, Inc.（a part of Collegium Pharmaceutical, Inc.）
    • Genentech, Inc.（Roche）
    • Alkermes.
    • Orexo US Inc.（subsidiary of Orexo AB）
    • Titan Pharmaceuticals, Inc.
    • Omeros Corporation
    • Camurus AB
    • Hikma Pharmaceuticals PLC
Product Code: GVR-3-68038-353-9

Opioid Use Disorder Market Growth & Trends:

The global opioid use disorder market size is expected to reach USD 10.24 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 11.15% from 2025 to 2030. Rising opioid epidemic and growing government initiatives to combat the crisis are likely to propel market growth. In addition, growing commercialization of novel products is further anticipated to drive growth. In 2018, about 2.9 million people aged 15 or above were suffering from this disorder in the U.S. In 2016, according to the National Survey on Drug Use and Health (NSDUH), in the U.S., around 11.5 million people had abused prescription opioids in the earlier year and more than 2 million were addicted to prescribed drugs.

According to the CDC, around 130 Americans die every day due to the opioid overdose and the U.S. government has designated this as a public health emergency.For patients wanting to overcome their addiction, adherence to a Medication-assisted Treatment (MAT) can reduce the withdrawal symptoms and cut the risk of death by half. Three U.S. FDA-approved MAT options are buprenorphine, methadone, and naltrexone. They are available in numerous dosages and formulations, with daily oral buprenorphine as the standard of care.

To combat the opioid crisis, several measures have been undertaken in recent years. For instance, in 2016, CDC clinical practice guidelines for prescribing these drugs for chronic pain were issued and new American Society of Addiction Medicine (ASAM) National Practice Guidelines was adopted in 2015 to improve standard of care. Furthermore, in 2016, the U.S. FDA announced plans to overhaul its regulations for abuse-deterrent opioids, enhance safety labeling, and re-examine the risk-benefit paradigm of their use.

Opioid Use Disorder Market Report Highlights:

  • Buprenorphine led the market and accounted for 59.58% of the global revenue in 2024 due to its effective dual action as a partial opioid agonist, which helps alleviate withdrawal symptoms and cravings while minimizing euphoria and misuse risk.
  • The injectable segment dominated the market and accounted for 59.26% of the global revenue in 2024. Extended release injectables, like Vivitrol (naltrexone) and Sublocade (buprenorphine), offer prolonged, steady drug delivery, improving adherence and reducing the risk of relapse.
  • Hospital pharmacies dominated the market with a market share of 47.90% in 2024 due to their integral role in managing complex and severe cases.
  • North America opioid use disorder market accounted for 68.98% share in 2024 due to several key factors. The region has the highest prevalence of OUD, which drives significant demand for treatment solutions.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary Distribution Channels
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Distribution Channels
  • 1.9. List of Primary Distribution Channels
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug
    • 2.2.2. Route of Administration
    • 2.2.3. Distribution Channel
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Opioid Use Disorder Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising opioid epidemic
      • 3.2.1.2. Growing government initiatives to combat the crisis
      • 3.2.1.3. Growing awareness of opioid use disorder (OUD)
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Adverse effects associated to drug used for opioid treatment
      • 3.2.2.2. Complex reimbursement structure
  • 3.3. Opioid Use Disorder Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Pricing Analysis
  • 3.5. Pipeline Analysis
  • 3.6. Qualitative analysis about Behavioral Therapies

Chapter 4. Opioid Use Disorder Market Analysis, by Drug, 2018-2030 (USD Million)

  • 4.1. Drug Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Opioid Use Disorder Market by Drug Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Buprenorphine
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Belbuca
        • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Suboxone
        • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Zubsolv
        • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Others
        • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Methadone
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Naltrexone
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Opioid Use Disorder Market Analysis, by Route of Administration, 2018-2030 (USD Million)

  • 5.1. Opioid Use Disorder: Route of Administration Movement Analysis
  • 5.2. Opioid Use Disorder Market Analysis, by Route of Administration Market (USD Million)
    • 5.2.1. Oral Administration
      • 5.2.1.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
    • 5.2.2. Injectable Administration
      • 5.2.2.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
    • 5.2.3. Others
      • 5.2.3.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)

Chapter 6. Opioid Use Disorder Market Analysis, by Distribution Channel, 2018-2030 (USD Million)

  • 6.1. Opioid Use Disorder: Distribution Channel Movement Analysis
  • 6.2. Opioid Use Disorder Market Analysis, by Distribution Channel Market (USD Million)
    • 6.2.1. Hospital Pharmacies
      • 6.2.1.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
    • 6.2.2. Retail Pharmacies
      • 6.2.2.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
    • 6.2.3. Others
      • 6.2.3.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)

Chapter 7. Opioid Use Disorder Market: Regional Estimates and Trend Analysis by Drug, by Route of Administration, by Distribution Channel

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Indivior PLC
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Drug benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Teva Pharmaceutical Industries, Ltd.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Drug benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Pfizer, Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Drug benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. BioDelivery Sciences International, Inc. (a part of Collegium Pharmaceutical, Inc.)
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Drug benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Genentech, Inc. (Roche)
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Drug benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Alkermes.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Drug benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Orexo US Inc. (subsidiary of Orexo AB)
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Drug benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Titan Pharmaceuticals, Inc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Drug benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Omeros Corporation
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Drug benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Camurus AB
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Drug benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Hikma Pharmaceuticals PLC
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Drug benchmarking
      • 8.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 4 Global opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 Global opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 North America opioid use disorder market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 8 North America opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 9 North America opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 11 U.S. opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 12 U.S. opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13 Canada opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 14 Canada opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 Canada opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Mexico opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 17 Mexico opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Mexico opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Europe opioid use disorder market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 21 Europe opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22 Europe opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 23 UK opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 24 UK opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 25 UK opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 26 Germany opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 27 Germany opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 Germany opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29 France opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 30 France opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 France opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32 Italy opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 33 Italy opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 34 Italy opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 35 Spain opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 36 Spain opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37 Spain opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 38 Norway opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 39 Norway opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 40 Norway opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Sweden opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 42 Sweden opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Sweden opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 Denmark opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 45 Denmark opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 46 Denmark opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific opioid use disorder market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 51 Japan opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 52 Japan opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 53 Japan opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 China opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 55 China opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 China opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 India opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 58 India opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 59 India opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 60 Australia opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 61 Australia opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 62 Australia opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 63 South Korea opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 64 South Korea opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 65 South Korea opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 Thailand opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 67 Thailand opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 68 Thailand opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Latin America opioid use disorder market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 71 Latin America opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 72 Latin America opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 73 Brazil opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 74 Brazil opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 75 Brazil opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 76 Argentina opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 77 Argentina opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 78 Argentina opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa opioid use disorder market, by country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83 South Africa opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 84 South Africa opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 85 South Africa opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 89 UAE opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 90 UAE opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 91 UAE opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 92 Kuwait opioid use disorder market, by drug, 2018 - 2030 (USD Million)
  • Table 93 Kuwait opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
  • Table 94 Kuwait opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Opioid use disorder market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Drug and route of administration segment snapshot
  • Fig. 11 Distribution channel snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Global Pharmaceutical Market (USD Billion)
  • Fig. 14 Market dynamics
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTLE analysis
  • Fig. 17 Opioid use disorder: Drug outlook and key takeaways
  • Fig. 18 Opioid use disorder market: Drug market movement analysis
  • Fig. 19 Naltrexone market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Buprenorphine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 BELBUCA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Sublocade market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Suboxone market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Zubsolv market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Other Buprenorphine products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Methadone market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Opioid use disorder: Route of administration outlook and key takeaways
  • Fig. 29 Opioid use disorder market: Route of administration market movement analysis
  • Fig. 30 Oral administration market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Injectable administration market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Opioid use disorder: Distribution channel outlook and key takeaways
  • Fig. 34 Opioid use disorder market: Distribution channel market movement analysis
  • Fig. 35 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Opioid use disorder market revenue, by region, 2023 & 2030, USD Million
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 U.S. opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 Canada opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Mexico opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Europe opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 UK opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Germany opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 France opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Spain opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Italy opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Denmark opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Sweden opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Norway opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Rest of Europe opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Japan opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 China opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 China regulatory details
  • Fig. 71 India opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Australia opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Thailand opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 South Korea opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Rest of Asia Pacific opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Latin America opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Brazil opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Brazil regulation details
  • Fig. 83 Key country dynamics
  • Fig. 84 Argentina opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Argentina regulatory framework
  • Fig. 86 Rest of Latin America opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 South Africa opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Saudi Arabia opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 UAE opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Kuwait opioid use disorder market estimates and forecasts, 2018
  • Fig. 95 Rest of MEA opioid use disorder market estimates and forecasts,
  • Fig. 96 Company/competition categorization
  • Fig. 97 Company market share analysis, 2024
  • Fig. 98 Strategy mapping